TECHNOLOGY
The Turbo Platform
Redefining Innate Immune Design for Bacterial Glycoconjugate Vaccines
The Scientific Challenge
Protein conjugation transformed bacterial vaccinology by converting poorly immunogenic polysaccharides into T cell-dependent antigens.
However, while adaptive immunity has been successfully engineered into glycoconjugate vaccines, the innate immune signals that initiate and shape durable protective immunity remain largely undefined.
Turbo was developed to address this unmet immunological need.
Our Discovery
Our research demonstrated that the baseline immunogenicity of bacterial glycoconjugate vaccines is influenced by residual innate immune impurities such as endotoxin.
Rather than relying on undefined impurities to stimulate immunity, Turbo provides a rational and reproducible approach to innate immune activation.
The Turbo Platform
Turbo is a proprietary immunological platform that integrates defined innate immune costimulation into bacterial glycoconjugate vaccines.
Unlike empirical adjuvant approaches, Turbo is designed around a mechanistically defined pathway that enhances the quality and durability of adaptive immune responses.
Mechanism of Action
Turbo activates defined innate immune signaling pathways that:
• Enhance antigen-presenting cell activation
• Promote germinal center formation
• Generates B cell memory
• Improve affinity maturation
• Balanced antibody response of all IgG classes
• Support long-lived plasma cell development
• Generate durable protective immunity
Why Turbo Matters
Turbo is designed to provide:
✓ Defined innate immune activation
✓ Improved durability of vaccine-induced immunity
✓ Reduced dependence on repeated booster immunizations
✓ Broad applicability across bacterial glycoconjugate vaccine platforms
✓ A scalable platform for future vaccine innovation
Scientific Validation
The Turbo platform has been validated through:
• Peer-reviewed publications
• Mechanistic immunology studies
• Multiple bacterial glycoconjugate vaccine models
• Intellectual property protecting the platform
Looking Forward
Turbo represents a new approach to bacterial vaccine design—one that combines adaptive immunity with rational innate immune engineering to improve the next generation of glycoconjugate vaccines.